Indicators

Latest News about ARGX

Recent news which mentions ARGX

< Previous 1 2 3 4 5 6 7 8 Next >

Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.

June 05, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023

May 31, 2023

Expert Ratings for argenx

May 31, 2023

Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday

May 05, 2023

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023

April 25, 2023

Analyst Ratings for argenx

April 21, 2023

7 Biotech Stocks That Could Cure Your Portfolio Woes

April 19, 2023

10 Health Care Stocks With Whale Alerts In Today's Session

April 12, 2023

A Bearish Sign Appears On argenx's Chart

March 23, 2023

Analyst Ratings for argenx

March 20, 2023

Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment

March 20, 2023

5 Analysts Have This to Say About argenx

March 03, 2023

Earnings Outlook For argenx

March 01, 2023

Immunovant Could Potentially Be An M&A Target, Writes Analyst

February 15, 2023

Analyst Ratings for argenx

January 10, 2023

AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday

January 10, 2023

Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday

December 22, 2022

Analyst Ratings for argenx

December 07, 2022

Expert Ratings for argenx

December 07, 2022

Stocks That Hit 52-Week Lows On Thursday

December 01, 2022

Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

November 30, 2022

Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review

November 22, 2022

McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday

October 28, 2022

Recap: argenx Q3 Earnings

October 27, 2022

7 Analysts Have This to Say About argenx

October 18, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022

October 12, 2022

Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say

September 29, 2022

Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection

September 21, 2022

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

August 11, 2022

Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate

August 11, 2022

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.